3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Completed
18
Terminated
7
Recruiting
5
Active not recruiting
2
Not yet recruiting
1
No longer available
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Myeloid
1
Conditions
Myelodysplastic Syndromes
25
Leukemia, Myeloid, Acute
24
Myeloproliferative Disorders
17
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
15
Polycythemia Vera
9
Primary Myelofibrosis
6
Precursor Cell Lymphoblastic Leukemia-Lymphoma
5
Leukemia, Myeloid, Chronic-Phase
4
Leukemia
4
Thrombocythemia, Essential
3
Lymphohistiocytosis, Hemophagocytic
3
Leukemia, Myelomonocytic, Chronic
3
Hematologic Neoplasms
3
Hematologic Diseases
3
Recurrence
2
Polycythemia
2
Myelodysplastic-Myeloproliferative Diseases
2
Motor Activity
2
Lymphoproliferative Disorders
2
Lymphoma, Non-Hodgkin
2
Lymphoma
2
Epstein-Barr Virus Infections
2
VEXAS syndrome
1
Thyroid Carcinoma, Anaplastic
1
Thyroid Cancer, Papillary
1
Thrombophilia
1
Thrombocytosis
1
Thrombocytopenia
1
Polycythemia, primary familial and congenital
1
Pleural Effusion, Malignant
1
Interventions
Quality of Life
1
Electrocardiography
1
Clinical Laboratory Techniques
1
Bone Marrow Examination
1
Azacitidine
1
11-(2-pyrrolidin-1-ylethoxy)-14,19-dioxa-5,7,26-triazatetracyclo(19.3.1.1(2,6).1(8,12))heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Not yet recruiting
×
Bone Marrow Diseases
×
Myeloid
×
Clear all
NCT07387354
2026-03-16
MDS
Thomas Jefferson University
Phase 1/2
Not yet recruiting
25 enrolled